VIVUS (VVUS), Orexigen (OREX) Higher Ahead of PDUFA; Arena (ARNA) Lags
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
VIVUS (Nasdaq: VVUS) shares are about 0.9 percent higher ahead of the bell Tuesday, heading into its PDUFA date with the FDA for proposed obesity drug Qnexa.
Shares are been stuck in the $26 to $30 range over the last month, having popped last on June 27th following FDA approval of Arena's (Nasdaq: ARNA) Belviq (lorcaserin).
Also making a big move this morning is Orexigen (Nasdaq: OREX), which is still running tests on its Contrave obesity pill. Orexigen has been on a hot-streak, having closed higher 10 of the last 14 sessions.
Arena is in negative territory in early trading.
Shares are been stuck in the $26 to $30 range over the last month, having popped last on June 27th following FDA approval of Arena's (Nasdaq: ARNA) Belviq (lorcaserin).
Also making a big move this morning is Orexigen (Nasdaq: OREX), which is still running tests on its Contrave obesity pill. Orexigen has been on a hot-streak, having closed higher 10 of the last 14 sessions.
Arena is in negative territory in early trading.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- Oncolytics reports preclinical data on pelareorep with RAS inhibitor
- Cullinan Therapeutics to host investor event after Phase 3 lung cancer trial data
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
